Stock SNES SENESTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings SenesTech, Inc.

Equities

SNES

US81720R5054

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.7285 USD -2.84% Intraday chart for SenesTech, Inc. +1.48% -42.64%
Feb. 26 Certain Warrants of SenesTech, Inc. are subject to a Lock-Up Agreement Ending on 26-FEB-2024. CI
Feb. 26 Certain Common Stock of SenesTech, Inc. are subject to a Lock-Up Agreement Ending on 26-FEB-2024. CI

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SENESTECH, INC. Stock SenesTech, Inc.
-42.64% 3.75M -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
A
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
B+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SNES Stock
  4. Ratings SenesTech, Inc.